

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

# Insulin icodec for treating type 1 and type 2 diabetes ID6175


## **Provisional Stakeholder List**

| Provisional Consultees  | Provisional Commentators (no right to submit or appeal)             |
|---|---|
|   | Submit of appeal)   |
| Company   | General   |
| Novo Nordisk (insulin icodec)   | All Wales Therapeutics and Toxicology                               |
| ,   | Centre  |
| Patient/carer groups  | Allied Health Professionals Federation                              |
| BEMDA: Black and Ethnic Minority  | Board of Community Health Councils in                               |
| Diabetes Association  | Wales   |
| Black Health Agency for Equality  | <ul> <li>British National Formulary</li> </ul>                      |
| Diabetes Research and Wellness  | Care Quality Commission   |
| Foundation  | <ul> <li>Department of Health, Social Services</li> </ul>           |
| Diabetes UK   | and Public Safety for Northern Ireland                              |
| InDependent Diabetes Trust  | Diabetes UK Cymru   |
| • JDRF  | Healthcare Improvement Scotland                                     |
| Muslim Council of Britain   | Medicines and Healthcare products                                   |
| Network of Sikh Organisations   | Regulatory Agency   |
| South Asian Health Foundation   | National Association of Primary Care                                |
| Specialised Healthcare Alliance   | National Pharmacy Association                                       |
| Healtheare professional groups  | NHS Confederation   |
| <ul><li>Healthcare professional groups</li><li>Association for the Study of Obesity</li></ul> | Scottish Medicines Consortium                                       |
| Association for the Study of Obesity     Association of British Clinical                      | Welsh Government     Walsh Haalth Spanished Comisses                |
| Diabetologists  | <ul> <li>Welsh Health Specialised Services<br/>Committee</li> </ul> |
| British Association for Nursing in  | Committee   |
| Cardiovascular Care   | Possible comparator companies                                       |
| British Geriatrics Society  | A. Menarini Farmaceutica  |
| British Heart Foundation  | Internazionale (canagliflozin, metformin)                           |
| British & Irish Hypertension Society  | Aurobindo Pharma (gliclazide,                                       |
| Primary Care Diabetes Society   | metformin, sitagliptin, vildagliptin)                               |
| Royal College of General Practitioners  | AstraZeneca (exenatide, dapagliflozin,                              |
| Royal College of Nursing  | metformin, saxagliptin)   |
| Royal College of Pathologists   | <ul> <li>Bioprojet (glibenclamide)</li> </ul>                       |
| Royal College of Physicians   | Boehringer Ingelheim (empagliflozin,                                |
| Royal Pharmaceutical Society  | linagliptin, metformin)   |
| Royal Society of Medicine   | Bristol laboratories (gliclazide)                                   |
| Society for Endocrinology   | Brown and Burk UK (gliclazide,                                      |
| TREND Diabetes  | glimepiride, metformin, pioglitazone)                               |
| UK Clinical Pharmacy Association  | <ul> <li>Celix Pharma (metformin, sitagliptin)</li> </ul>           |

Provisional stakeholder list for the evaluation of insulin icodec for treating type 1 and type 2 diabetes ID6175



| Provisional Consultees  | Provisional Commentators (no right to submit or appeal)   |
|---|---|
| Others  • Department of Health and Social Care  • NHS England | <ul> <li>Colonis Pharma (metformin)</li> <li>Dr Reddy's Laboratories (metformin, sitagliptin)</li> <li>Eli Lilly (dulaglutide, insulin, tirzepatide)</li> <li>Flamingo Pharma (gliclazide)</li> <li>Genus Pharmaceuticals (metformin, sitagliptin)</li> <li>Glenmark Pharmaceuticals (metformin, sitagliptin)</li> <li>Ipca Laboratories (metformin)</li> <li>Krka UK (gliclazide, sitagliptin)</li> <li>Lupin Healthcare (gliclazide)</li> <li>Morningside Healthcare (metformin)</li> <li>MSD (ertugliflozin, metformin, sitagliptin)</li> <li>Mylan (gliclazide, insulin, pioglitazone, sitagliptin)</li> <li>Neon Healthcare (metformin, pioglitazone)</li> <li>Novartis (metformin, vildagliptin)</li> <li>Novo Nordisk (insulin, liraglutide, semaglutide)</li> <li>Pfizer (glipizide)</li> <li>Pinewood Healthcare (metformin)</li> <li>Ranbaxy (sitagliptin)</li> <li>Rosemont Pharmaceuticals (metformin)</li> <li>Sandoz (metformin, pioglitazone)</li> <li>Sanofi (insulin, lixisenatide)</li> <li>Servier Laboratories (gliclazide)</li> <li>Sigma Pharmaceuticals (metformin)</li> <li>Sovereign Medical (tolbutamide)</li> <li>Strides Pharma (metformin)</li> <li>Takeda (alogliptin, metformin)</li> <li>Takeda (alogliptin, metformin)</li> <li>Thame Laboratories (metformin, sitagliptin)</li> <li>Tillomed Laboratories (metformin)</li> <li>Wockhardt (metformin)</li> <li>Zentiva (gliclazide, metformin, sitagliptin)</li> </ul> |
|   | Relevant research groups  Cochrane Metabolic & Endocrine Disorders Group  |



| Provisional Consultees | Provisional Commentators (no right to submit or appeal)   |
|------------------------|---|
|                        | <ul> <li>Cochrane UK</li> <li>Genomics England</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li>The Society for Research in Rehabilitation</li> <li>Wellcome Trust</li> </ul> |
|                        | <ul> <li>Associated Public Health groups</li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>   |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).


All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These

Provisional stakeholder list for the evaluation of insulin icodec for treating type 1 and type 2 diabetes ID6175





organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.